文献速递类风湿关节炎

口服避孕药与绝经激素治疗对类风湿关节炎风险的影响:一项前瞻性队列研究

Effects of oral contraceptives and menopausal hormone therapy on the risk of rheumatoid arthritis: a prospective cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于英国生物银行(UK Biobank)白人女性前瞻性队列(口服避孕药分析 n=236 602,绝经激素治疗分析 n=102 466),采用时间依赖 Cox 回归分析,并在全部族裔女性中重复验证。口服避孕药使用与类风湿关节炎风险降低相关(曾用者 HR=0.89,95%CI 0.82-0.96),而绝经激素治疗与晚发性类风湿关节炎风险升高相关(曾用者 HR=1.16,95%CI 1.06-1.26)。

要点

  • 口服避孕药曾用者较从未使用者类风湿关节炎风险降低(HR=0.89,95%CI 0.82-0.96)。
  • 绝经激素治疗曾用者较从未使用者晚发性类风湿关节炎风险升高(HR=1.16,95%CI 1.06-1.26)。
  • 作者认为口服避孕药似乎对类风湿关节炎有保护作用,而绝经激素治疗可能增加晚发性类风湿关节炎风险。

核心结论

  • 作者认为口服避孕药使用似乎对类风湿关节炎有保护作用,而绝经激素治疗可能增加晚发性类风湿关节炎风险。
  • 本研究为不同外源性性激素暴露与类风湿关节炎风险之间可能存在的相反效应提供了新见解。

研究设计与样本

  • 研究采用时间依赖 Cox 回归模型,分析英国生物银行(UK Biobank)白人女性中口服避孕药与类风湿关节炎的关联(n=236 602)以及绝经激素治疗与晚发性类风湿关节炎的关联(n=102 466)。
  • 研究在全部族裔女性中对上述关联进行了重复验证。

主要发现

  • 与从未使用者相比,口服避孕药曾用者类风湿关节炎风险降低(HR=0.89,95%CI 0.82-0.96)。
  • 与从未使用者相比,口服避孕药当前使用者类风湿关节炎风险降低(HR=0.81,95%CI 0.73-0.91)。
  • 与从未使用者相比,口服避孕药既往使用者类风湿关节炎风险降低(HR=0.92,95%CI 0.84-1.00)。
  • 与从未使用者相比,绝经激素治疗曾用者晚发性类风湿关节炎风险升高(HR=1.16,95%CI 1.06-1.26)。
  • 与从未使用者相比,绝经激素治疗既往使用者晚发性类风湿关节炎风险升高(HR=1.13,95%CI 1.03-1.24)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Oral contraceptives (OC) and menopausal hormone therapy (MHT) contain exogenous sex hormones and are used by millions of women around the world. However, their effect on the development of rheumatoid arthritis (RA) is still debated and the current literature suggests that they may exert opposite effects on the risk of RA. The present study aimed to estimate the effects of exogenous hormones on the development of RA, both during the reproductive lifespan and later in life. METHODS: The association between OC and RA, as well as between MHT and late-onset RA (LORA), was investigated using time-dependent Cox regression modelling in white British women from the UK Biobank (n = 236 602 and n = 102 466, respectively) and replicated in women from all ethnic groups. RESULTS: OC use was associated with a decreased risk of RA in ever-users [hazard ratio (HR) = 0.89; 95% CI = 0.82-0.96], as well as in current (HR = 0.81; 0.73-0.91) and former users (HR = 0.92; 0.84 -1.00), compared with never-users. In contrast, MHT use was associated with an increased risk of LORA in ever-users (HR = 1.16; 1.06-1.26) as well as in former users (HR = 1.13; 1.03-1.24) compared with never-users. CONCLUSION: OC use appears to protect against RA, while MHT may increase the risk of LORA. This study provides new insights into the possible inverse effect of exposure to different exogenous sex hormones on the risk of RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hadizadeh F, Johansson T, Johansson Å, et al. Effects of oral contraceptives and menopausal hormone therapy on the risk of rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford). 2024. PMID: 37773999. doi:10.1093/rheumatology/kead513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。